First case series on the use of imiquimod for morphoea

Summary Background Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)‐β. Objective Our objective was to use imiquimod 5% cream (Aldara™), an inducer of interferon‐γ, known to inhibit TGF‐β, to treat morphoea. Methods Patients with morphoea were treated with imiquimod and evaluated during their follow‐up visits to 6 months. Results The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. Conclusion This is the first case series describing the successful application of imiquimod in the management of morphoea.